Icagen, Pfizer sign CNS deal; collaboration continues
Executive Summary
Icagen (developing small-molecule therapeutics that modulate ion channels) and Pfizer will ally in the discovery, development, and commercialization of compounds against three of Icagen's sodium ion channel targets for pain and related CNS disorders such as epilepsy.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice